Navigation Links
Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer

SOUTH SAN FRANCISCO, Calif., April 03, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced final, updated results from its second multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer which evaluated escalating doses of the immunotherapy in 80 patients with metastatic hormone-refractory prostate cancer (HRPC). Additional follow-up of the 22 patients who received the dose that is comparable to that being employed in the company's ongoing Phase 3 program indicates that the median survival is 35.0 months. Four patients have withdrawn consent to further follow-up and thus were censored in the analysis. The company previously reported final median survival results from its first multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer in 34 patients with metastatic HRPC that showed an overall median survival of 26.2 months. The survival results from the two, independent multi-center Phase 2 clinical trials compare favorably to the previously published median survival of 18.9 months for metastatic hormone-refractory prostate cancer patients treated with Taxotere(R) (docetaxel) chemotherapy plus prednisone, the current standard of care for these patients. The company's ongoing Phase 3 program is designed to confirm this potential survival benefit for GVAX immunotherapy for prostate cancer.

"We are certainly encouraged by the survival data from the second Phase 2 trial of GVAX immunotherapy for prostate cancer. The final median survival of 35.0 months also compares favorably to a predicted median survival of 22.0 months for these 22 patients based on a validated, published nomogram using seven prognostic variables," stated Rob Dow, M.D., chief medical officer of Cell Genesys. "We continue to hope that GVAX immunotherapy for prostate cancer may some day offer a new treatment option for patients with this disease."

GVAX immunotherapy for prostate cancer is currently
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
2. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. XTL Provides Update on Phase I Clinical Trial of XTL-2125
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
7. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
8. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
9. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
10. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
11. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
Post Your Comments:
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group finds ... growth factor (VEGF) agent for wet AMD, is equally ... plans as Genentech,s Lucentis, which is the standard of ... care organization (MCO) directors do not identify a clear ... more likely than Lucentis to be listed on tier ...
(Date:9/18/2014)... 18, 2014  A $3 million grant from The ... of Michigan to establish a national center of excellence ... for Aging Research at U-M will focus on exploiting ... the effects of aging and postpone diseases in animal ... can help develop medications that may help people live ...
(Date:9/18/2014)... 2014  Halozyme Therapeutics, Inc. (NASDAQ: ... and Drug Administration (FDA) has removed the clinical ... in SWOG,s ongoing Phase 1b/2 clinical trial (S1313). ... drug PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination ... metastatic pancreatic adenocarcinoma.  The study will resume under ...
Breaking Medicine Technology:Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4
(Date:9/18/2014)... Angeles, CA (PRWEB) September 18, 2014 ... manufacture and refine carbon dioxide, selling it to downstream ... largest markets for carbon dioxide are food and beverage ... products, such as fruits, vegetables or pizzas. The gas ... Beverage manufacturers use the compound to carbonate soft drinks, ...
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 (HealthDay ... can quickly alter the way brain cells communicate with one ... Sept. 18 in Current Biology , are a step ... Experts said the hope is to eventually be able to ... a drug -- and which people would fare better with ...
(Date:9/18/2014)... of Chest Physicians (CHEST) together with the Chinese ... congress of CTS that CHEST World Congress 2016 ... pulmonary, critical care, and sleep medicine from around ... event, slated for spring 2016. , CHEST ... including hands-on simulation training, keynote addresses, presentations by ...
(Date:9/18/2014)... UT (PRWEB) September 18, 2014 Thousands ... will be recognizing their shared fundraising impact on 127 ... Sept. 25. , The first-ever Dance Marathon Day will ... $20 million projected to be raised by college and ... CMN Hospital. Donations generated through Dance Marathon campus programs ...
(Date:9/18/2014)... 2014 Stealth Health Revolution co-founders, ... and Frank Davis, founder of Food for Health ... pleased to announce the new recipe book, "The ... nutrition-packed meals using Activz whole-food powders." The ... in the Stealth Health Revolution mission ...
Breaking Medicine News(10 mins):Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:CHEST announces China as site of CHEST World Congress 2016 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 3
... Institute researchers will lead a symposium on relationships between ... autism in children during the American Association for the ... in Vancouver, Canada. The symposium, "Autism: Genetic, Epigenetic ... Feb. 18. The researchers, both affiliated with the UC ...
... FRIDAY, Feb. 17 (HealthDay News) -- Knees with osteoarthritis are ... are not, researchers say. The discovery was a surprise, ... and immunology at Duke University Medical Center in Durham, N.C. ... we didn,t know about and the main treatment strategy probably ...
... researchers are expressing concern about a new, under-recognized, much ... surfaced in the U.S. "Historically, in Western countries, ... have caused infections mostly in sick, hospitalized patients whose ... professor in the Department of Medicine at the UB ...
... the job in the U.S. each year, and millions more ... a worker,s perception of safety in the workplace and the ... on-the-job injury. "We,ve known for some time that certain ... of physical and other hazards," said Dave DeJoy, UGA professor ...
... the pioneering days of the juvenile corrections system, social ... rehabilitated young offenders. As the field of corrections became ... workers was marginalized. A University of Missouri expert on ... return to the juvenile corrections system and reclaim their ...
... Esposito HealthDay Reporter , FRIDAY, Feb. 17 ... good helmet fit might help reduce loss of consciousness ... new study finds. Expensive, high-tech helmets with air-lining ... concussions, the researchers said. "The occurrence of concussion ...
Cached Medicine News:Health News:UC Davis MIND Institute researchers to present on autism at AAAS Annual Meeting in Vancouver 2Health News:Arthritic Hip May Be Tougher to Treat Than Knee 2Health News:Nasty 'superbug' is being studied by UB researchers 2Health News:Nasty 'superbug' is being studied by UB researchers 3Health News:Perception, work-life balance key factors in workplace safety, says UGA study 2Health News:Perception, work-life balance key factors in workplace safety, says UGA study 3Health News:Social workers should reclaim role in juvenile corrections system, MU researcher says 2Health News:Good Football Helmet Fit Key to Preventing Brain Injuries 2Health News:Good Football Helmet Fit Key to Preventing Brain Injuries 3
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
Only Mobile Instrument offers complete repair and rebuild capability on all makes and models of endoscopy and laparoscopy instruments, using only factory-quality parts and precision techniques....
... Broken, burnt or damaged fiber optics reduce the ... a substantial decrease in the optical clarity that ... optic instrumentation is essential to prevent further damage ... Mobile Instrument technician can inspect your cables for ...
... camera upon arrival.,Our technician then makes note of ... a thorough customer quote. We respect that you ... well help you prioritize repairs. With customer approval, ... ISI uses only OEM or widely approved equivalent ...
Medicine Products: